MIRA™ is a miRNA-based endometrial receptivity test that determines the optimal time for embryo transfer.
Our microRNA (miRNA) biomarkers allow for a less invasive biopsy procedure and more reliable results, increasing the chances of a successful IVF treatment cycle.
We support healthcare professionals worldwide in their efforts to raise IVF success rates. Our solution provides valuable insight during the IVF treatment cycle to ensure individualized care for patients.
Learn HowWe work to stay at the forefront of the issues families face when undergoing IVF, partnering with healthcare professionals to deliver better testing solutions for patients.
Learn How
Inti Labs collaborates with clinics, service providers, and distributors worldwide to deliver impactful solutions to fertility specialists and their patients.
Our tests are designed to offer more accurate, less-invasive solutions, reducing the likelihood of additional treatment cycles while enhancing the overall patient experience.
Inti Labs continues to progress the reproductive healthcare landscape for professionals and families, empowering each to make the most informed decisions regarding their treatment plan.
Inti Labs’ Chief Technology Officer Dr. Barry Behr is a renowned embryologist with an extensive history of oocyte (egg) and embryo research.
Keep an eye on our blog, where Dr. Behr will be sharing bite-sized insights into what goes on in an IVF lab.
